‹ ›
MYP_102445
← PREVIOUS NEXT → BACK
Basic Information
MCo-SST-02
Anticancer
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
32 amino acids
C162H255N51O41S6
Standard
Sequence
CPKILKKCRRDSDCPGACICRGNGYCRFWKTW
Physicochemical Analysis
3765.47 Da
9.34
5.70
5.40
0.1781
-0.65
0.69
-0.25
40.08
39.69
0.1250
12490.00
12865.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1509.48
-14.52
61.0
53.0
121.0
260.0
8.0
32.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0040143 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
mixed L/D amino-acid peptide [Mixed]
None
None
w=D-Tryptophane
Bio-Activity Profile
Antimicrobial Anticancer
PC-3
83.55±0.2 μM
IC50
PaperDual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci Rep. 2016 Oct 13;6:35347. doi: 10.1038/srep35347. PMID: 27734947. PMID27734947 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/27734947/
RECORD: Rec_0064994 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
mixed L/D amino-acid peptide [Mixed]
None
None
w=D-Tryptophane
Bio-Activity Profile
Antimicrobial Anticancer Cytotoxic
HUVEC
100 μM
IC50
PaperDual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci Rep. 2016 Oct 13;6:35347. doi: 10.1038/srep35347. PMID: 27734947. PMID27734947 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/27734947/
RECORD: Rec_0114932 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
mixed L/D amino-acid peptide [Mixed]
None
None
w=D-Tryptophane
Bio-Activity Profile
Antimicrobial Anticancer
MCF-7
70.61±0.11 μM
IC50
PaperDual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci Rep. 2016 Oct 13;6:35347. doi: 10.1038/srep35347. PMID: 27734947. PMID27734947 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/27734947/
RECORD: Rec_0157678 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
mixed L/D amino-acid peptide [Mixed]
None
None
w=D-Tryptophane
Bio-Activity Profile
Antimicrobial Anticancer
HT-29
58.89±0.09 μM
IC50
PaperDual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci Rep. 2016 Oct 13;6:35347. doi: 10.1038/srep35347. PMID: 27734947. PMID27734947 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/27734947/
RECORD: Rec_0297809 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
mixed L/D amino-acid peptide [Mixed]
None
None
w=D-Tryptophane
Bio-Activity Profile
Antimicrobial Anticancer
Human red blood cells: no hemolytic activity(as show in Fig.4)
PaperDual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci Rep. 2016 Oct 13;6:35347. doi: 10.1038/srep35347. PMID: 27734947. PMID27734947 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/27734947/